Research programme: nanoparticle therapeutics - LTT Bio-Pharma

Drug Profile

Research programme: nanoparticle therapeutics - LTT Bio-Pharma

Alternative Names: LT-0111; Nano-steroid 1

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator LTT Bio-Pharma
  • Class Steroids
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Rheumatoid-arthritis in Japan
  • 17 Aug 2015 LTT Bio-Pharma and Beijing Tide Pharmaceutical agree to co-develop the nano-particle formulation before August 2015 (http://ltt.co.jp/english/souyaku02.html)
  • 17 Aug 2015 LTT Bio-Pharma has international patent protection for nanoparticles for drug delivery
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top